ERFO — Laboratorio Farmaceutico Erfo SpA Share Price
Last trade - 00:00- €9.19m
- €9.69m
- €9.49m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.56 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -7.26% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.12 | ||
| Price to Tang. Book | 3.05 | ||
| Price to Free Cashflow | 7.32 | ||
| Price to Sales | 0.96 | ||
| EV to EBITDA | 4.85 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.25% | ||
| Return on Equity | 4.9% | ||
| Operating Margin | 11.46% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 4.82 | 4.62 | 5.74 | 5.83 | 9.49 | 9.6 | 11 | 19.45% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +3.05 | -39.03 | -16.16 | -14.65 | +30.97 | +74.26 | -15.38 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Laboratorio Farmaceutico Erfo SpA is an Italy-based pharmaceutical company primarily engaged in the nutraceutical sector. The Company specializes in the production of nutritional supplements, that thanks to research and development carried out internally and in collaboration with the University Campus Bio-Medico of Rome and the University of Messina provides products with a scientific value in different therapeutic areas. The Company operates globally.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- January 1st, 1970
- Public Since
- June 29th, 2022
- No. of Employees
- 50
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Borsa Italiana
- Shares in Issue
- 8,505,000
- Address
- Viale Geki Russo, VILLAFRANCA TIRRENA, 98049
- Web
- https://www.erfo.it
- Phone
- +39 null0909146125
- Contact
- Alessandro Cute
- Auditors
- BDO Italia S.p.A.
Similar to ERFO
PharmaNutra
Borsa Italiana
Recordati Industria Chimica e Farmaceutica
Borsa Italiana
FAQ
As of Today at 20:43 UTC, shares in Laboratorio Farmaceutico Erfo SpA are trading at €1.08. This share price information is delayed by 15 minutes.
Shares in Laboratorio Farmaceutico Erfo SpA last closed at €1.08 and the price had moved by -31.21% over the past 365 days. In terms of relative price strength the Laboratorio Farmaceutico Erfo SpA share price has underperformed the FTSE Global All Cap Index by -40.1% over the past year.
The overall consensus recommendation for Laboratorio Farmaceutico Erfo SpA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreLaboratorio Farmaceutico Erfo SpA does not currently pay a dividend.
Laboratorio Farmaceutico Erfo SpA does not currently pay a dividend.
Laboratorio Farmaceutico Erfo SpA does not currently pay a dividend.
To buy shares in Laboratorio Farmaceutico Erfo SpA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €1.08, shares in Laboratorio Farmaceutico Erfo SpA had a market capitalisation of €9.19m.
Here are the trading details for Laboratorio Farmaceutico Erfo SpA:
- Country of listing: Italy
- Exchange: MIL
- Ticker Symbol: ERFO
Based on an overall assessment of its quality, value and momentum Laboratorio Farmaceutico Erfo SpA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Laboratorio Farmaceutico Erfo SpA is €1.80. That is 66.67% above the last closing price of €1.08.
Analysts covering Laboratorio Farmaceutico Erfo SpA currently have a consensus Earnings Per Share (EPS) forecast of €0.13 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Laboratorio Farmaceutico Erfo SpA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -10.08%.
As of the last closing price of €1.08, shares in Laboratorio Farmaceutico Erfo SpA were trading -8.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Laboratorio Farmaceutico Erfo SpA PE ratio based on its reported earnings over the past 12 months is 9.56. The shares last closed at €1.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Laboratorio Farmaceutico Erfo SpA's management team is headed by:
- Alessandro Cute - CHM
- Flavio Corpina - CEO
- Fabio Giuffre - IND